Company and Industry Summary Company:倍加洁 (Beijiajie) Production Capacity - Current production capacity of Shanenkang's raw probiotic powder is 40 tons, with an additional 24 tons expected to be added by June-July 2026, involving an investment of approximately 30 million [1] - The company adheres to a "small steps, steady expansion" strategy, focusing on improving utilization rates of limited capacity and developing downstream customers [1] - In the event of a market explosion for AKK, the company plans to reallocate capacity from traditional probiotics to AKK [1] - Existing capacity is shared, and due to sales exceeding output in 2025, the BC01 strain has been outsourced to a factory in Changzhou for production [1] Core Advantages - The company's probiotic products possess a "three good" advantage: good activity, good safety, and good scientific basis [1] - It has mastered core technologies for the preparation of the next generation of probiotics, with clear strain sources and safety assessment reports, as well as whole genome testing reports [1] - Validation through in vitro cell tests, various models, and clinical trials has been conducted [1] Competitive Strategy - Future market competition will be addressed through a tiered product strategy, including high-end AKK Probio (retail price of 9,000 yuan/kg), mid-range AKK one/AKK META, and white-label brands (priced at 2,000-3,000 yuan/kg with no additional R&D investment) [2] Customer Base - The primary downstream customers are large brand merchants such as RuYuchen and Xianle, as well as offline major clients [3] Performance Goals - The overall revenue target for Shanenkang in 2026 is 180 million, with a specific target of 50 million for AKK business (based on an average price of 5,000 yuan/kg, requiring 10 tons of capacity) [3] - The expected overall net profit margin is over 20%, aiming to achieve a non-recurring net profit commitment of approximately 40 million for the listed company [3] - The group aims to achieve a revenue target of around 2.5 billion within 3-5 years, with Shanenkang targeting 500 million in revenue by 2027-2028 [3] Shareholding Structure - The listed company holds 52.06% of Shanenkang's shares, with an equity stake of 57% (the difference is due to reserved equity for employee stock incentives that have not yet been implemented) [3] Future Considerations - If performance targets are met, equity will be gradually released according to the investment agreement, and there is a possibility of a spin-off listing in the future, subject to regulatory approval [4] - If performance targets are not met, a renegotiation of equity arrangements will be necessary [5]